Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.73 |
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | JUN | P05412 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24617861 | 0.91 | ALOX5 (0.74) | ALOX5APPJUNNFKB1KDM4E | |
| SCHEMBL8034404 | 0.91 | ALOX5 (0.79) | ALOX5JUNNFKB1KDM4EJAK2 | |
| SCHEMBL28181780 | 0.86 | ALOX5 (0.72) | ALOX5JUNNFKB1KDM4EJAK2 | |
| SCHEMBL15384911 | 0.84 | ALOX5 (0.66) | ALOX5APPNFKB1KDM4EALDH1A1 | |
| SCHEMBL29120857 | 0.82 | ALOX5 (0.68) | ALOX5APPJUNNFKB1 | |
| SCHEMBL13498777 | 0.81 | ALOX5 (0.68) | ALOX5JUNNFKB1KDM4EJAK2 | |
| SCHEMBL15378926 | 0.81 | TTR (0.74) | ALOX5APPNFKB1KDM4EALDH1A1 | |
| SCHEMBL8031865 | 0.81 | ALOX5 (0.68) | ALOX5JUNNFKB1KDM4EJAK2 | |
| SCHEMBL2602745 | 0.81 | TTR (0.74) | ALOX5APPNFKB1KDM4EALDH1A1 | |
| SCHEMBL13997727 | 0.81 | ALOX5 (0.56) | ALOX5JUNNFKB1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841066-B1 | ANTI-INFLUENZA AGENT CONJUGATED TO ANTI-INFLAMMATORY AGENT | ACADEMIA SINICA (TW) | 2021-02-17 | — | — | EP | disclosed |
| EP-3524272-A1 | ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY | Academia Sinica (TW) | 2019-08-14 | — | — | EP | disclosed |
| US-20130274229-A1 | ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY | ACADEMIA SINICA (TW) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274229-A1 | ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY | NEU1, CTSA, CA7 | ALOX5 229/4885APP 4018/4885JUN 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.